Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents
DOI:
https://doi.org/10.1590/0101-60830000000007Abstract
Background Psychostimulants (methylphenidate and amphetamines) are considered first-line therapy for attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine dimesylate (LDX) is a new psychostimulant approved for the treatment of ADHD in Brazil. The pharmacologically active fraction, d-amphetamine, is gradually released by hydrolysis of the LDX prodrug. Objectives To perform a systematic review of the literature of the efficacy and safety of LDX in the treatment of ADHD in children and adolescents. Methods Medline/PubMed searches for “d-amfetamine”, “lisdexamfetamine” and “lisdexamfetamine dimesylate” were conducted including articles available from January 2000 to November 2013. Additional references were identified using references listed in those articles. Further data on LDX were requested from its manufacturer. Results Thirty-one papers were found related to ADHD treatment in children and adolescents. Discussion The therapeutic benefits of LDX in children with ADHD are achieved as early as 1.5 hours after its administration and last for up to 13 hours, with efficacy comparable or superior to that of other available psychostimulants. The literature also reports efficacy in long-term treatment, with safety and tolerability profiles comparable to those of other stimulants used for the treatment of ADHD. Most of the adverse events associated with LDX are considered to be mild or moderate in severity, with the most common being loss of appetite and insomnia.Downloads
Download data is not yet available.
Downloads
Published
2014-03-01
Issue
Section
Review Article
License
Once accepted for publication, the manuscript becomes permanent property of the Archives of Clinical Psychiatry. This copyright transfer subsumes exclusive and unlimited entitlement of the Archives of Clinical Psychiatry to publish and distribute the full contents of articles in whichever publishing medium, including press and electronic media, in Brazil and abroad.
Manuscripts are accepted with the understanding that the Editor and the editorial staff have the right to make revisions aimed at greater conciseness, clarity, and conformity with Journal style, of course without changing its content.
How to Cite
Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents . (2014). Archives of Clinical Psychiatry, 41(2), 34-39. https://doi.org/10.1590/0101-60830000000007